Cargando…
Effective therapeutic management of hepatocellular carcinoma – on the basis of a clinical case
The prognosis of patients suffering from primary hepatocellular carcinoma (HCC) is unfavourable because the tumour usually develops in cirrhosis-affected liver and is typically not diagnosed until an advanced stage of the disease. The 5-year survival rate for HCC patients in Europe does not exceed 9...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687383/ https://www.ncbi.nlm.nih.gov/pubmed/23788857 http://dx.doi.org/10.5114/wo.2012.27339 |
_version_ | 1782273913167806464 |
---|---|
author | Omyła-Staszewska, Joanna Deptała, Andrzej |
author_facet | Omyła-Staszewska, Joanna Deptała, Andrzej |
author_sort | Omyła-Staszewska, Joanna |
collection | PubMed |
description | The prognosis of patients suffering from primary hepatocellular carcinoma (HCC) is unfavourable because the tumour usually develops in cirrhosis-affected liver and is typically not diagnosed until an advanced stage of the disease. The 5-year survival rate for HCC patients in Europe does not exceed 9%. On the basis of a clinical case, the present article discusses the strategy of treatment of HCC patients. Patients with advanced HCC, stage C according to the Barcelona Clinic Liver Cancer (BCLC) staging system, typically receive systemic chemotherapy with sorafenib. The standard management in the treatment of intermediate-stage HCC, i.e. BCLC's stage B, is chemoembolization (TACE). However, repeated TACE sessions activate factors involved in the process of angiogenesis such as hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF), which can render the procedure ineffective. Therefore, there are scientific foundations for combining TACE with antiangiogenic agents such as sorafenib. Results of studies conducted to date indicate that the combination of sorafenib with TACE in patients with BCLC's stage B brings tangible therapeutic effects while being safe. The value of this therapeutic strategy is confirmed by the case described below, in which TACE + sorafenib have induced a partial regression of HCC. |
format | Online Article Text |
id | pubmed-3687383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-36873832013-06-20 Effective therapeutic management of hepatocellular carcinoma – on the basis of a clinical case Omyła-Staszewska, Joanna Deptała, Andrzej Contemp Oncol (Pozn) Case Report The prognosis of patients suffering from primary hepatocellular carcinoma (HCC) is unfavourable because the tumour usually develops in cirrhosis-affected liver and is typically not diagnosed until an advanced stage of the disease. The 5-year survival rate for HCC patients in Europe does not exceed 9%. On the basis of a clinical case, the present article discusses the strategy of treatment of HCC patients. Patients with advanced HCC, stage C according to the Barcelona Clinic Liver Cancer (BCLC) staging system, typically receive systemic chemotherapy with sorafenib. The standard management in the treatment of intermediate-stage HCC, i.e. BCLC's stage B, is chemoembolization (TACE). However, repeated TACE sessions activate factors involved in the process of angiogenesis such as hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF), which can render the procedure ineffective. Therefore, there are scientific foundations for combining TACE with antiangiogenic agents such as sorafenib. Results of studies conducted to date indicate that the combination of sorafenib with TACE in patients with BCLC's stage B brings tangible therapeutic effects while being safe. The value of this therapeutic strategy is confirmed by the case described below, in which TACE + sorafenib have induced a partial regression of HCC. Termedia Publishing House 2012-02-29 2012 /pmc/articles/PMC3687383/ /pubmed/23788857 http://dx.doi.org/10.5114/wo.2012.27339 Text en Copyright © 2012 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Omyła-Staszewska, Joanna Deptała, Andrzej Effective therapeutic management of hepatocellular carcinoma – on the basis of a clinical case |
title | Effective therapeutic management of hepatocellular carcinoma – on the basis of a clinical case |
title_full | Effective therapeutic management of hepatocellular carcinoma – on the basis of a clinical case |
title_fullStr | Effective therapeutic management of hepatocellular carcinoma – on the basis of a clinical case |
title_full_unstemmed | Effective therapeutic management of hepatocellular carcinoma – on the basis of a clinical case |
title_short | Effective therapeutic management of hepatocellular carcinoma – on the basis of a clinical case |
title_sort | effective therapeutic management of hepatocellular carcinoma – on the basis of a clinical case |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687383/ https://www.ncbi.nlm.nih.gov/pubmed/23788857 http://dx.doi.org/10.5114/wo.2012.27339 |
work_keys_str_mv | AT omyłastaszewskajoanna effectivetherapeuticmanagementofhepatocellularcarcinomaonthebasisofaclinicalcase AT deptałaandrzej effectivetherapeuticmanagementofhepatocellularcarcinomaonthebasisofaclinicalcase |